BC99 for Allergic Rhinitis: Why Age May Change the Biology

Weizmannia coagulans BC99 improved allergic rhinitis symptoms in two 2025 placebo-controlled trials, one in children and one in adults. The intriguing part is the biology each study captured: children showed changes in gut bacteria, fecal short-chain fatty acids, and immune markers; adults showed changes in oxidative-stress markers and serum metabolites. That could mean age changes how this probiotic works. It could also mean the studies measured different things and then invited us to connect the dots.

The second explanation deserves more respect. Both trials used the same intervention—BC99 at 2×10⁹ CFU daily for eight weeks—and both reported statistically significant symptom improvement. But neither trial measured the other trial's main mechanistic endpoints. Until a study tests gut, immune, oxidative-stress, and metabolic outcomes in both children and adults, "different mechanisms by age" remains a plausible hypothesis, not a discovery.

Same strain, two different measurement panels

A 2025 randomized, double-blind, placebo-controlled trial in children enrolled 52 participants with allergic rhinitis. After eight weeks of BC99 or placebo, investigators assessed symptoms, quality of life, serum immune markers, fecal short-chain fatty acids (SCFAs), and gut microbiota with 16S rRNA sequencing.

A separate 2025 randomized, double-blind, placebo-controlled adult trial enrolled 78 people: 40 received BC99 and 38 received placebo. It used the same daily dose and treatment duration, but examined superoxide dismutase (SOD), glutathione (GSH), malondialdehyde (MDA), serum IgA, complement proteins C3 and C4, plus untargeted serum metabolomics. It did not sequence the gut microbiome or measure fecal SCFAs.

Both trials reported statistically significant clinical improvement, but neither publication provides the between-group mean differences or standardized effect sizes needed to judge the size of the benefit. The pediatric study reported improvement in RCAT and RQLQ scores at p<0.01. The available evidence also does not establish whether changes in TNSS, RCAT, or RQLQ reached a minimally clinically important difference. Statistical significance can tell us that a result is unlikely to be random under a study's assumptions; it does not tell us whether a patient would notice a large enough change to care about it.

What changed in children

In the pediatric trial, BC99 was associated with a coherent gut-and-immune pattern. Fecal Bifidobacterium and Roseburia increased, while Escherichia-Shigella and Collinsella declined. Fecal acetate, butyrate, and isovalerate also rose. These are SCFAs, microbial fermentation products that can influence immune signaling.

Serum IgE, IL-4, IL-13, and TNF-α decreased, while IFN-γ and the IFN-γ/IL-4 ratio increased; the reported biomarker changes had p values below 0.05. In allergic rhinitis, IL-4 and IL-13 are associated with type 2 immune activity, so this pattern fits a shift away from a Th2-skewed response. It does not prove that the altered gut taxa caused the cytokine changes, or that the cytokines caused the symptom changes. The trial measured these outcomes over the same intervention period; it did not experimentally isolate a causal chain.

The authors also reported predicted changes in pathways such as PPAR signaling and purine metabolism. Those predictions came from 16S amplicon data, not direct measurement of microbial genes, proteins, or pathway activity. Treat them as leads for a future experiment, not as a map of what BC99 definitively did inside a child's gut.

The gut-SCFA explanation has support beyond BC99

The pediatric results do not stand alone. A 2022 systematic review and meta-analysis pooling 26 randomized trials found that probiotic therapy broadly improved pediatric allergic-rhinitis outcomes, including symptoms, IgE, and quality of life. It did not include BC99, so it cannot supply a BC99-specific effect estimate or prove that every probiotic works the same way. Still, it places the pediatric result inside a larger body of treatment evidence.

Gut biology also remains relevant outside childhood. In a 2024 double-blind trial of a probiotic-plus-prebiotic synbiotic in adults with seasonal allergic rhinitis, microbiota remodeling and SCFA-related changes correlated with symptom improvement. Correlation is not proof of mediation, but it shows that a gut-SCFA pathway is a credible target in adult allergic rhinitis as well.

A 2025 systematic review and meta-analysis of gut microbiota and allergic rhinitis also found that allergic rhinitis is associated with differences in gut microbiota composition. Association studies cannot show that dysbiosis causes allergic rhinitis, but they support the biological rationale for testing microbiota-directed treatments. A separate 2025 cross-sectional study found distinct gut-microbiota alterations in young children with functional constipation and allergic-rhinitis comorbidity. Its population had an additional condition, so it should not be treated as a general description of every child with allergic rhinitis.

What changed in adults—and what the study missed

The adult BC99 trial reported significant clinical improvement alongside changes in SOD, GSH, MDA, complement-related measures, and serum metabolic profiles. These findings make oxidative stress and systemic metabolism reasonable hypotheses for further work. They do not establish that oxidative stress was the primary route through which BC99 improved symptoms.

The study's biggest limitation is simple: it did not measure the gut outcomes that defined the pediatric trial. Adults may have experienced the same microbiota and SCFA changes, a different pathway, both pathways, or neither. We cannot choose among those possibilities from the existing data. The pediatric study has the reciprocal problem because it did not include an oxidative-stress panel.

Two trials can reveal an interesting contrast without conducting the comparison needed to explain it.

The adult study also ran during a single October-to-December 2024 seasonal window. Allergic exposure can vary substantially during a season, and an eight-week study cannot establish whether benefits persist after supplementation stops. BC99 gummies were supplied by Wecare Probiotics Co., Ltd.; industry product supply does not invalidate a trial, but replication by independent groups matters, especially for a strain with only these two published human randomized trials in allergic conditions.

Why adult probiotic claims need a higher bar

Other adult trials offer signals, not consensus. A 2023 placebo-controlled trial of a multispecies probiotic for seasonal allergic rhinitis characterized the field as early-phase clinical research. A 2024 exploratory randomized trial of a four-strain blend reported symptom and fecal-microbiota findings, but enrolled only 41 participants in total (19 probiotic and 22 placebo). Different mixtures, populations, outcome tools, and designs mean these trials cannot be averaged into a claim that probiotics have one established adult mechanism.

Nor can success in children be generalized across every allergic context. A 2025 Cochrane review found insufficient evidence that probiotics prevent allergic disease in infants. Prevention in infancy is a different question from treating established allergic rhinitis in school-age children or adults, but the distinction matters. Probiotic effects depend on strain, timing, population, disease, and endpoint.

What to do with BC99 now

BC99 has a credible early clinical signal: two small double-blind, placebo-controlled eight-week trials, at 2×10⁹ CFU per day, reported statistically significant allergic-rhinitis symptom improvement in children and adults. The pediatric rationale is better characterized because the trial measured a linked set of microbiome, SCFA, immune, and patient-facing outcomes. The adult findings are promising but incomplete because the study did not test whether the gut pathway was active.

For researchers, the next study is obvious: use the same protocol across age groups and measure symptoms, quality of life, fecal microbiota, SCFAs, immune markers, oxidative-stress markers, and serum metabolites in everyone. It should also report between-group effect sizes, clinical-importance thresholds, longer follow-up, and replication outside Chinese populations. Until then, BC99 is evidence for a short-term treatment signal—not proof that children and adults respond through separate biological routes.